RU2012109006A - Инсулинсодержащий фармацевтический препарат для перорального применения - Google Patents

Инсулинсодержащий фармацевтический препарат для перорального применения Download PDF

Info

Publication number
RU2012109006A
RU2012109006A RU2012109006/15A RU2012109006A RU2012109006A RU 2012109006 A RU2012109006 A RU 2012109006A RU 2012109006/15 A RU2012109006/15 A RU 2012109006/15A RU 2012109006 A RU2012109006 A RU 2012109006A RU 2012109006 A RU2012109006 A RU 2012109006A
Authority
RU
Russia
Prior art keywords
insulin
pharmaceutical preparation
preparation according
dosage form
aminocaproic acid
Prior art date
Application number
RU2012109006/15A
Other languages
English (en)
Russian (ru)
Inventor
Др. Зольтан СИЛЬВАШШИ
Др. Барна ПЕИТЛЬ
Др. Йожеф НЕМЕТ
Original Assignee
Цера-Мед Кфт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цера-Мед Кфт. filed Critical Цера-Мед Кфт.
Publication of RU2012109006A publication Critical patent/RU2012109006A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2012109006/15A 2009-08-03 2010-08-02 Инсулинсодержащий фармацевтический препарат для перорального применения RU2012109006A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP0900482 2009-08-03
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
RU2012109006A true RU2012109006A (ru) 2013-09-10

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012109006/15A RU2012109006A (ru) 2009-08-03 2010-08-02 Инсулинсодержащий фармацевтический препарат для перорального применения

Country Status (15)

Country Link
US (1) US20120129769A1 (enExample)
EP (1) EP2461820A1 (enExample)
JP (1) JP2013501043A (enExample)
KR (1) KR20120088660A (enExample)
CN (1) CN102791282A (enExample)
AU (1) AU2010280418B2 (enExample)
BR (1) BR112012002413A2 (enExample)
CA (1) CA2769620A1 (enExample)
HU (1) HUP0900482A2 (enExample)
IL (1) IL217856A0 (enExample)
MX (1) MX2012001461A (enExample)
RU (1) RU2012109006A (enExample)
UA (1) UA106506C2 (enExample)
WO (1) WO2011015984A1 (enExample)
ZA (1) ZA201201519B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726091B1 (en) * 2011-06-29 2020-01-22 Rani Therapeutics, LLC Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3067713A1 (en) * 2017-06-28 2019-01-03 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit U Method for determining the risk to develop type 1 diabetes
KR20240171428A (ko) 2023-05-30 2024-12-09 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
EP0351651B1 (en) 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
DK0615444T3 (da) 1991-12-05 1996-07-08 Alfatec Pharma Gmbh Peroral indgivelsesform til peptidlægemidler, især insulin
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
EP0803255A4 (en) * 1994-06-03 1999-06-30 Tsumura & Co MEDICINAL COMPOSITION
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
CN1259045A (zh) 1997-04-02 2000-07-05 普渡研究基金会 蛋白质的口服释放方法
CN1329502A (zh) 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 含有胰岛素的药物组合物
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
ATE485051T1 (de) 2003-03-04 2010-11-15 Technology Dev Company Ltd Injizierbare insulinzubereitung mit langzeitwirkung und verfahren zur dessen herstellung und verwendung
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
US9259456B2 (en) * 2005-09-06 2016-02-16 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062408B (zh) * 2006-04-27 2010-12-08 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
EP2164466A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物

Also Published As

Publication number Publication date
US20120129769A1 (en) 2012-05-24
IL217856A0 (en) 2012-03-29
CN102791282A (zh) 2012-11-21
WO2011015984A1 (en) 2011-02-10
ZA201201519B (en) 2013-05-29
BR112012002413A2 (pt) 2016-03-01
AU2010280418A1 (en) 2012-03-22
KR20120088660A (ko) 2012-08-08
HU0900482D0 (en) 2009-10-28
JP2013501043A (ja) 2013-01-10
AU2010280418B2 (en) 2015-04-09
HUP0900482A2 (en) 2011-03-28
CA2769620A1 (en) 2011-02-10
UA106506C2 (uk) 2014-09-10
MX2012001461A (es) 2012-05-22
EP2461820A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
Tulipano et al. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors
ES2440289T3 (es) Preparación que comprende insulina, nicotinamida y arginina
JP7546622B2 (ja) 活性薬剤の経口投与のための製剤
CN107427481A (zh) 骨质疏松症的治疗
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
RU2009111391A (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
JP2019533722A5 (enExample)
SI3068796T1 (en) Calcitonin mimetics for the treatment of diseases and disorders
NZ600477A (en) Insulin analogues with chlorinated amino acids
CN103097405B (zh) 用于伤口愈合的新型肽
MY190257A (en) Optimised subcutaneous therapeutic agents
RU2012109006A (ru) Инсулинсодержащий фармацевтический препарат для перорального применения
JP2023517616A (ja) 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤
WO2007061829A3 (en) Pharmaceutical composition
JP2021185201A (ja) コラーゲン７組成物及びそれを用いる方法
CA3184145A1 (en) C-type natriuretic peptides and methods thereof in treating acute lung injury
DK2374468T3 (da) Anvendelse af peptid af APL-typen til behandling af inflammatoriske tarmsygdomme og type 1-diabetes
WO2016122806A8 (en) Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
JP6471366B2 (ja) インクレチンホルモン又はそのアナログを用いた変形性関節症の処置
CN104031141A (zh) 用于治疗2型糖尿病的长效肠激素多肽类似物及应用
JPWO2009107766A1 (ja) 経鼻投与用医薬組成物
JP2015524808A5 (enExample)
WO2021226244A1 (en) Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
WO2012130193A1 (en) Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
WO2015035405A1 (en) Myostatin antagonist for treatment of pew in esrd patients